Emzor: Local Drug Manufacturing, APIs Crucial to Ending Malaria Burden in Nigeria

Emzor Pharmaceutical Industries Limited has called for increased investment in local drug production and Active Pharmaceutical Ingredients (APIs) as Nigeria marks World Malaria Day 2026, stressing that these measures are key to eliminating malaria.

Referencing data from the World Health Organization, the company noted that Nigeria carries the highest global malaria burden, accounting for 27 per cent of cases and nearly one-third of related deaths, particularly affecting children under five.

Executive Director Uzoma Ezeoke said sustained progress would depend on building a resilient health system supported by local pharmaceutical manufacturing.

She said:
“Local manufacturing is no longer optional; it is central to our national health security and the sustainability of malaria control efforts.

“We must build a system where high-quality, WHO-compliant antimalarials are produced locally to close access gaps and protect against global supply disruptions.”

Ezeoke stressed that eliminating malaria would require joint efforts from government, policymakers, development partners, and private sector stakeholders.

Chairman of Emzor Group, Emeka Okoli, described API production as the “next frontier” in strengthening Nigeria’s pharmaceutical sector.

He said:
“Ending malaria sustainably requires pharmaceutical independence.

“Investing in API manufacturing will strengthen the entire value chain, reduce reliance on imports, and position Nigeria as a regional hub while ensuring consistent access to life-saving medicines.”

He added that local production would boost employment opportunities and enhance quality control in line with international standards.

The company also highlighted its role in expanding access to WHO-approved antimalarial drugs, including child-friendly dispersible options designed to improve treatment outcomes for children.

Ezeoke added:
“Malaria continues to place a heavy burden on our most vulnerable populations, and our response must reflect that reality.

“Our focus is not just on producing medicines, but on ensuring they are practical, accessible, and effective for those who need them most, especially children and pregnant women.”

Emzor further emphasised preventive care for pregnant women as a key strategy in reducing complications.

Okoli concluded with a call to action:
“Now is the time to move from commitment to execution.

“With the right investments and partnerships, Nigeria can build a self-reliant pharmaceutical sector capable of ending malaria. Now we can. Now we must act.”

Africans Angle News